Faldaprevir

SKU: orb1706015

Description

Faldaprevir is a potent and selective non-covalent inhibitor of the HCV NS3/4A protease, effective against genotypes 1a and 1b. It blocks viral polyprotein processing, inhibiting replication, and has demonstrated antiviral activity in both in vitro assays and clinical research studies for hepatitis C.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 801283-95-4
• MW: 869.82
• Purity: >99.99% (May vary between batches)
• Formula: C₄₀H₄₉BrN₆O₉S
• SMILES: N(C(=O)[C@H]1N(C([C@@H](NC(OC2CCCC2)=O)C(C)(C)C)=O)C[C@H](OC=3C4=C(N=C(C3)C=5N=C(NC(C(C)C)=O)SC5)C(Br)=C(OC)C=C4)C1)[C@@]6(C(O)=O)[C@H](C=C)C6
• Target: HCV Protease
• Solubility: DMSO:4 mg/mL (4.6 mM)

Bioactivity

• In Vivo:
  Methods: After a single intravenous injection of 2 mg/kg or 10 mg/kg oral administration of [(14)C]-Faldaprevir in rats, the metabolism, pharmacokinetics, excretion, and tissue distribution of the hepatitis C NS3/NS4 protease inhibitor were studied. Results: After intravenous administration, the terminal elimination of plasma radioactivity was 1.75 h (male) and 1.74 h (female) respectively. The corresponding AUC0-∞, CL and Vss were 1920 and 1900 ngEq · h/mL, 18.3 and 17.7 mL/min/kg and 2.32 and 2.12 mL/kg for men and women, respectively. After oral administration, the plasma radioactivity of t1/2 and AUC0-∞ was 1.67 and 1.77 h and 11 300 and 17 900 ngEq · h/mL for men and women, respectively.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Faldaprevir, BI201335, BI-201335, BI 201335

Compound Identifiers

PubChem CID

42601552